AcneNCT07127523
A Clinical Trial to Investigate the Efficacy and Safety of GenLabs' Social Renew on Improving Acne Symptoms and Skin Repair Among Healthy Adults
A study testing Social Renew in people with Acne, run by GenCanna Acquisition Corp at 1 site in Canada.
Trial summary
The goal of this interventional clinical trial is to investigate the efficacy and safety of GenLabs' Social Renew on improving acne symptoms and skin repair among healthy adults. Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Acne
- What is being tested?
- Social Renew
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 150 participants
- Where
- 1 siteCanada
- Study dates
- Jul 2026to Sep 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Males and females between 18 and 65 years of age inclusive
- Females not of child-bearing potential, defined as those who have undergone a sterilization procedure (e.g. hysterectomy, bilateral oophorectomy, bilateral tubal ligation, complete endometrial ablation) or have been post-menopausal for at least 1 year prior to screening
- Or,
- Individuals of child-bearing potential must self-report confirmation they are not pregnant, do not plan to become pregnant, and agree to use a medically approved method of birth control for the duration of the study. All hormonal birth control must have been in use for a minimum of three months. Acceptable methods of birth control include:
- Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System)
- Double-barrier method
Show all 17Show fewer
- Intrauterine devices
- Non-heterosexual lifestyle or agrees to use contraception if planning on changing to heterosexual partner(s)
- Vasectomy of partner at least 6 months prior to screening
- Abstinence
- Experience acne on facial skin that is visible to the participant and is confirmed by the QI at screening and at baseline
- Willingness to complete questionnaires and diaries associated with the study, to capture and upload photos, and to complete all virtual visits
- Willingness to maintain the same skincare regimen throughout the study, including maintaining make-up routine without the addition of new make-up products
- Agrees to maintain current lifestyle habits (diet, physical activity, medications, supplements, and sleep) as much as possible throughout the study
- Provided voluntary, written, informed consent to participate in the study
- Agrees to have de-identified photos of face available for marketing purposes
- Self-reported healthy as determined by medical history with no unstable diagnosed medical conditions
Who cannot join
- Individuals who are pregnant, breast feeding, or planning to become pregnant during the study
- Self-reported allergy, sensitivity or intolerance to investigational product or placebo ingredients, including allergy to salicylic acid or any form of salicylates, preventing topical use
- Individuals with significant facial hair that would impede the visualization of facial acne and may interfere with the use of the product, such as beards and long sideburns, as assessed by the QI
- Self-reported psoriasis, dermatitis, vitiligo, or any other active dermatological condition other than acne affecting the face
- Self-reported use of topical products on the face marked with claims relating to skin health, or those with claims relating to acne during the study, except for noncomedogenic moisturizers and sunscreen
- Self-reported shaving, waxing, tweezing, or threading of the face or use of nose/facial strips within 3 days prior to each photo capture
Show all 29Show fewer
- Procedures such as microdermabrasion, peels, acne treatments, filler, botulinum toxin, red light therapy, pore suction therapy, or laser on the face within three months of baseline
- Self-reported UVA or UVB exposure to the face in the past two weeks or expected during the study to avoid sunburn.
- Current use of prescribed and/or over-the-counter (OTC) medications, supplements, and/or consumption of food/drinks that may impact the efficacy and/or safety of the investigational product (Sections 7.3.1 and 7.3.2)
- Self-reported asthma
- Self-reported presence of a peptic ulcer
- Self-reported autoimmune disease or are immune compromised
- Self-reported ongoing and unstable diseases/conditions in the past three months, including:
- Arthritis and joint diseases
- Gastrointestinal diseases
- Hypertension
- Type I or type II diabetes
- Cardiovascular disease
- Kidney diseases
- Liver diseases
- Thyroid condition
- Psychiatric conditions
- Major surgery in the past 3 months or individuals who have planned surgery during the course of the study
- Cancer, except skin basal cell carcinoma completely excised with no chemotherapy or radiation with a follow up that is negative. Volunteers with cancer in full remission for more than five years after diagnosis are acceptable
- Alcohol intake average of >2 standard drinks per day
- Alcohol or drug abuse within the last 12 months
- Participation in other clinical research studies 30 days prior to screening
- Individuals who are unable to give informed consent
- Any other condition or lifestyle factor that may adversely affect the participant's ability to complete the study or its measures or pose significant risk to the participant
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Canada1 site
KGK Science Inc.
London, Ontario, N6B3L1
Marc Moulin, PhD, 2893800976, bhallam@kgkscience.com
bhallam@kgkscience.com
About this study
Official title: A Randomized, Triple-blind, Placebo Controlled, Parallel Virtual Clinical Trial to Investigate the Efficacy and Safety of GenLabs' Social Renew on Improving Acne Symptoms and Skin Repair Among Healthy Adults
The goal of this interventional clinical trial is to investigate the efficacy and safety of GenLabs' Social Renew on improving acne symptoms and skin repair among healthy adults. The main question[s] it aims to answer is:
What is the difference in the change in acne symptoms as assessed by the Acne Quality of Life Questionnaire (ACNE-QoL) between GenLabs' Social Renew and placebo from baseline at Day 30.
- Conditions
- Acne
- Being tested
- Social Renew, Placebo
- Keywords
- GenLabs, Acne symptoms, Social Renew
- Medical subject headings
- Acne Vulgaris
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Social RenewOther
This group receives a cleanser, serum, and cream.
PlaceboOther
This group receives a cleanser, serum, and cream.
| Study group | Role | What they receive |
|---|---|---|
| Social Renew | Experimental | The investigational product in this study contains ProRenew Complex CLRTM, which is a three-step skin regime targeting acne comprised of Lactococcus ferment lysate, derived from L. lactis, in addition to peppermint, willow bark, and lentil seed extracts. Apply the 3 study products in the morning and at night before bed. The participants will be required to maintain their application times throughout the study duration. Application of the study products covering the face will occur in a step-wise fashion (Step 1, Step 2, Step 3) for 30 days. Receives: Other: Social Renew |
| Placebo | Placebo comparator | This group receives a placebo containing non-medicinal ingredients in Social Renew, in a three-step skin regime. Apply the 3 study products in the morning and at night before bed. The participants will be required to maintain their application times throughout the study duration. Application of the study products covering the face will occur in a step-wise fashion (Step 1, Step 2, Step 3) for 30 days. Receives: Other: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
The difference in the change in acne symptoms as assessed by the Acne Quality of Life Questionnaire (ACNE-QoL) between GenLabs' Social Renew and placebo
The difference in the change in acne symptoms as assessed by the Acne Quality of Life Questionnaire (ACNE-QoL) between GenLabs' Social Renew and placebo from baseline at Day 30. The Acne symptoms domain of the Acne-QoL is comprised of 5 questions which assess the physical symptoms experienced by facial acne sufferers. Questions include the number of bumps on the face, the extent of scabbing from the acne, and the level of worry associated with scarring from the acne.
Measured: Day 0 to 30
Secondary outcomes (14)
The difference in the change in acne symptoms as assessed by the Acne Quality of Life Questionnaire (ACNE-QoL) between GenLabs' Social Renew
The difference in the change in acne symptoms as assessed by the Acne Quality of Life Questionnaire (ACNE-QoL) between GenLabs' Social Renew and placebo from baseline at Day 10
Measured: Day 0 to 10
The difference in the change in acne symptoms as assessed by the Acne Quality of Life Questionnaire (ACNE-QoL) between GenLabs' Social Renew
The difference in the change in acne symptoms as assessed by the Acne Quality of Life Questionnaire (ACNE-QoL) between GenLabs' Social Renew and placebo from baseline at Day 20.
Measured: Day 0 to 20
The difference in change in acne symptoms as assessed by the Self-assessment of Clinical Acne-Related Scars (SCARS) between GenLabs' Social Renew and placebo
The difference in change in acne symptoms as assessed by the Self-assessment of Clinical Acne-Related Scars (SCARS) between GenLabs' Social Renew and placebo from baseline at Day 10. The SCARS has two parts, part 1 asks questions related to current active acne including zits, breakouts, pimpled, whiteheads, and blackheads, and questions related to atrophic scaring including indents or holes in the skin from previous active acne. Part 2 of the SCARS, assess acne scar appearance and severity with 5 questions such as how much of your face is covered by indents or holes with five potential answers: almost none of my face, a little of my face, some of my face, a lot of my face, and almost all of my face
Measured: Day 0 to 10
The difference in change in acne symptoms as assessed by the Self-assessment of Clinical Acne-Related Scars (SCARS) between GenLabs' Social Renew and placebo
The difference in change in acne symptoms as assessed by the Self-assessment of Clinical Acne-Related Scars (SCARS) between GenLabs' Social Renew and placebo from baseline at Day 20. The SCARS has two parts, part 1 asks questions related to current active acne including zits, breakouts, pimpled, whiteheads, and blackheads, and questions related to atrophic scaring including indents or holes in the skin from previous active acne. Part 2 of the SCARS, assess acne scar appearance and severity with 5 questions such as how much of your face is covered by indents or holes with five potential answers: almost none of my face, a little of my face, some of my face, a lot of my face, and almost all of my face
Measured: Day 0 to 20
The difference in change in acne symptoms as assessed by the Self-assessment of Clinical Acne-Related Scars (SCARS) between GenLabs' Social Renew and placebo
The difference in change in acne symptoms as assessed by the Self-assessment of Clinical Acne-Related Scars (SCARS) between GenLabs' Social Renew and placebo from baseline at Day 30. The SCARS has two parts, part 1 asks questions related to current active acne including zits, breakouts, pimpled, whiteheads, and blackheads, and questions related to atrophic scaring including indents or holes in the skin from previous active acne. Part 2 of the SCARS, assess acne scar appearance and severity with 5 questions such as how much of your face is covered by indents or holes with five potential answers: almost none of my face, a little of my face, some of my face, a lot of my face, and almost all of my face
Measured: Day 0 to 30
The difference in change in self-perception, social impact, and emotional impact as measured by the ACNE-QoL between GenLabs' Social Renew and placebo
The difference in change in self-perception, social impact, and emotional impact as measured by the ACNE-QoL between GenLabs' Social Renew and placebo from baseline at Day 10
Measured: Day 0 to 10
The difference in change in self-perception, social impact, and emotional impact as measured by the ACNE-QoL between GenLabs' Social Renew and placebo
The difference in change in self-perception, social impact, and emotional impact as measured by the ACNE-QoL between GenLabs' Social Renew and placebo from baseline at Day 10
Measured: Day 0 to 20
The difference in change in self-perception, social impact, and emotional impact as measured by the ACNE-QoL between GenLabs' Social Renew and placebo
The difference in change in self-perception, social impact, and emotional impact as measured by the ACNE-QoL between GenLabs' Social Renew and placebo from baseline at Day 10
Measured: Day 0 to 30
The difference in change in acne appearance as assessed by the participant and investigator using the Global Aesthetic Improvement Scale (GAIS) between GenLabs' Social Renew and placebo
The difference in change in acne appearance as assessed by the participant and investigator using the Global Aesthetic Improvement Scale (GAIS) between GenLabs' Social Renew and placebo from baseline at Day 10. The GAIS categorizes acne improvement according to a five-point scale (1 - Very much improved, 2 - Much improved, 3- Improved, 4- No change, 5- Worsened).
Measured: Day 0 to 10
The difference in change in acne appearance as assessed by the participant and investigator using the Global Aesthetic Improvement Scale (GAIS) between GenLabs' Social Renew and placebo
The difference in change in acne appearance as assessed by the participant and investigator using the Global Aesthetic Improvement Scale (GAIS) between GenLabs' Social Renew and placebo from baseline at Day 20. The GAIS categorizes acne improvement according to a five-point scale (1 - Very much improved, 2 - Much improved, 3- Improved, 4- No change, 5- Worsened).
Measured: Day 0 to 20
The difference in change in acne appearance as assessed by the participant and investigator using the Global Aesthetic Improvement Scale (GAIS) between GenLabs' Social Renew and placebo
The difference in change in acne appearance as assessed by the participant and investigator using the Global Aesthetic Improvement Scale (GAIS) between GenLabs' Social Renew and placebo from baseline at Day 30
Measured: Day 0 to 30
The difference in change in acne scar appearance as assessed by the participant using the Vancouver Scar Scale (VSS) between GenLabs' Social Renew and placebo
The difference in change in acne scar appearance as assessed by the participant using the Vancouver Scar Scale (VSS) between GenLabs' Social Renew and placebo from baseline at Day 10. The VSS is scored out of a total of 13 with a higher score denoting a more severe scar appearance.
Measured: Day 0 to 10
The difference in change in acne scar appearance as assessed by the participant using the Vancouver Scar Scale (VSS) between GenLabs' Social Renew and placebo
The difference in change in acne scar appearance as assessed by the participant using the Vancouver Scar Scale (VSS) between GenLabs' Social Renew and placebo from baseline at Day 20. The VSS is scored out of a total of 13 with a higher score denoting a more severe scar appearance.
Measured: Day 0 to 20
The difference in change in acne scar appearance as assessed by the participant using the Vancouver Scar Scale (VSS) between GenLabs' Social Renew and placebo
The difference in change in acne scar appearance as assessed by the participant using the Vancouver Scar Scale (VSS) between GenLabs' Social Renew and placebo from baseline at Day 30. The VSS is scored out of a total of 13 with a higher score denoting a more severe scar appearance.
Measured: Day 0 to 30
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Aug 2025
- Study startJul 2026 (estimated)
- Primary completionSep 2026 (estimated)
- Study completionSep 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for AcneStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 150 participants (estimated)
Sponsor and investigators
- Lead sponsor
- GenCanna Acquisition Corp
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- KGK Science Inc.
- Responsible party
- Sponsor
- Investigators
- David Crowley, MD, Principal investigator, KGK Science Inc.
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07127523
- Sponsor's protocol ID
- 25GCCFT01
- Status last verified
- Jun 2026
- First submitted
- 11 Aug 2025
- Last updated
- 30 Jun 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 30 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized, Triple-blind, Placebo Controlled, Parallel Virtual Clinical Trial to Investigate the Efficacy and Safety of GenLabs' Social Renew on Improving Acne Symptoms and Skin Repair Among Healthy Adults
- ClinicalTrials.gov ID
- NCT07127523
- Acronym / sponsor ID
- 25GCCFT01
- Conditions
- Acne
- Keywords
- GenLabs, Acne symptoms, Social Renew
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 150 participants (estimated)
- Lead sponsor
- GenCanna Acquisition CorpIndustry (pharma, biotech, devices)
- Collaborators
- KGK Science Inc.
- Study start
- Jul 2026 (estimated)
- Primary completion
- Sep 2026 (estimated)
- Study completion
- Sep 2026 (estimated)
- First posted
- 17 Aug 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this interventional clinical trial is to investigate the efficacy and safety of GenLabs' Social Renew on improving acne symptoms and skin repair among healthy adults. The main question[s] it aims to answer is:
What is the difference in the change in acne symptoms as assessed by the Acne Quality of Life Questionnaire (ACNE-QoL) between GenLabs' Social Renew and placebo from baseline at Day 30.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Social Renew | Experimental | Other: Social RenewThe investigational product in this study contains ProRenew Complex CLRTM, which is a three-step skin regime targeting acne comprised of Lactococcus ferment lysate, derived from L. lactis, in addition to peppermint, willow bark, and lentil seed extracts. Apply the 3 study products in the morning and at night before bed. The participants will be required to maintain their application times throughout the study duration. Application of the study products covering the face will occur in a step-wise fashion (Step 1, Step 2, Step 3) for 30 days. |
| Placebo | Placebo comparator | Other: PlaceboThis group receives a placebo containing non-medicinal ingredients in Social Renew, in a three-step skin regime. Apply the 3 study products in the morning and at night before bed. The participants will be required to maintain their application times throughout the study duration. Application of the study products covering the face will occur in a step-wise fashion (Step 1, Step 2, Step 3) for 30 days. |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (17 listed)
- Males and females between 18 and 65 years of age inclusive
- Females not of child-bearing potential, defined as those who have undergone a sterilization procedure (e.g. hysterectomy, bilateral oophorectomy, bilateral tubal ligation, complete endometrial ablation) or have been post-menopausal for at least 1 year prior to screening
- Or,
- Individuals of child-bearing potential must self-report confirmation they are not pregnant, do not plan to become pregnant, and agree to use a medically approved method of birth control for the duration of the study. All hormonal birth control must have been in use for a minimum of three months. Acceptable methods of birth control include:
- Experience acne on facial skin that is visible to the participant and is confirmed by the QI at screening and at baseline
Key exclusion criteria (29 listed)
- Individuals who are pregnant, breast feeding, or planning to become pregnant during the study
- Self-reported allergy, sensitivity or intolerance to investigational product or placebo ingredients, including allergy to salicylic acid or any form of salicylates, preventing topical use
- Individuals with significant facial hair that would impede the visualization of facial acne and may interfere with the use of the product, such as beards and long sideburns, as assessed by the QI
- Self-reported psoriasis, dermatitis, vitiligo, or any other active dermatological condition other than acne affecting the face
- Self-reported use of topical products on the face marked with claims relating to skin health, or those with claims relating to acne during the study, except for noncomedogenic moisturizers and sunscreen
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Social RenewThis group receives a cleanser, serum, and cream. | Other | Social Renew |
| PlaceboThis group receives a cleanser, serum, and cream. | Other | Placebo |
Primary outcome
The difference in the change in acne symptoms as assessed by the Acne Quality of Life Questionnaire (ACNE-QoL) between GenLabs' Social Renew and placebo
Time frame: Day 0 to 30
The difference in the change in acne symptoms as assessed by the Acne Quality of Life Questionnaire (ACNE-QoL) between GenLabs' Social Renew and placebo from baseline at Day 30. The Acne symptoms domain of the Acne-QoL is comprised of 5 questions which assess the physical symptoms experienced by facial acne sufferers. Questions include the number of bumps on the face, the extent of scabbing from the acne, and the level of worry associated with scarring from the acne.
14 secondary outcomes
The difference in the change in acne symptoms as assessed by the Acne Quality of Life Questionnaire (ACNE-QoL) between GenLabs' Social Renew
Time frame: Day 0 to 10
The difference in the change in acne symptoms as assessed by the Acne Quality of Life Questionnaire (ACNE-QoL) between GenLabs' Social Renew
Time frame: Day 0 to 20
The difference in change in acne symptoms as assessed by the Self-assessment of Clinical Acne-Related Scars (SCARS) between GenLabs' Social Renew and placebo
Time frame: Day 0 to 10
The difference in change in acne symptoms as assessed by the Self-assessment of Clinical Acne-Related Scars (SCARS) between GenLabs' Social Renew and placebo
Time frame: Day 0 to 20
The difference in change in acne symptoms as assessed by the Self-assessment of Clinical Acne-Related Scars (SCARS) between GenLabs' Social Renew and placebo
Time frame: Day 0 to 30
The difference in change in self-perception, social impact, and emotional impact as measured by the ACNE-QoL between GenLabs' Social Renew and placebo
Time frame: Day 0 to 10
The difference in change in self-perception, social impact, and emotional impact as measured by the ACNE-QoL between GenLabs' Social Renew and placebo
Time frame: Day 0 to 20
The difference in change in self-perception, social impact, and emotional impact as measured by the ACNE-QoL between GenLabs' Social Renew and placebo
Time frame: Day 0 to 30
The difference in change in acne appearance as assessed by the participant and investigator using the Global Aesthetic Improvement Scale (GAIS) between GenLabs' Social Renew and placebo
Time frame: Day 0 to 10
The difference in change in acne appearance as assessed by the participant and investigator using the Global Aesthetic Improvement Scale (GAIS) between GenLabs' Social Renew and placebo
Time frame: Day 0 to 20
The difference in change in acne appearance as assessed by the participant and investigator using the Global Aesthetic Improvement Scale (GAIS) between GenLabs' Social Renew and placebo
Time frame: Day 0 to 30
The difference in change in acne scar appearance as assessed by the participant using the Vancouver Scar Scale (VSS) between GenLabs' Social Renew and placebo
Time frame: Day 0 to 10
The difference in change in acne scar appearance as assessed by the participant using the Vancouver Scar Scale (VSS) between GenLabs' Social Renew and placebo
Time frame: Day 0 to 20
The difference in change in acne scar appearance as assessed by the participant using the Vancouver Scar Scale (VSS) between GenLabs' Social Renew and placebo
Time frame: Day 0 to 30
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Jun 2026.
Related trials for Acne
Not yet recruitingPhase 3
Evaluation of the Efficacy and Safety of Fractional CO₂ Laser With and Without Intradermal Botulinum Toxin A in the Treatment of Inflammatory Facial Acne Vulgaris.
Acne, Acne Papulopustulosa
RecruitingPhase 4
Safety, Tolerability, and Clinical Effectiveness of Adapalene/Clindamycin Phosphate Gel (Klenzit®-C) in Vietnamese Patients With Mild to Moderate Acne Vulgaris
Acne
RecruitingPhase 3
Phase 3 Study of Denifanstat in Participants With Moderate to Severe Acne (AURORA)
Acne Vulgaris
RecruitingPhase 4
Comparing Nadifloxacin Plus Tretinoin Versus Clindamycin Plus Tretinoin Creams for Mild-to-Moderate Acne
Acne Vulgaris
Active, not recruiting
Clinical Study to Evaluate the Safety and Efficacy of Candela Technology
Hair Reduction, Tattoo Removal
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
David Crowley, MD principal investigator
KGK Science Inc.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Social Renew in people with Acne, run by GenCanna Acquisition Corp at 1 site in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 17 inclusion and 29 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 30 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Marc Moulin, PhD (2267819094, mmoulin@kgkscience.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The difference in the change in acne symptoms as assessed by the Acne Quality of Life Questionnaire (ACNE-QoL) between GenLabs' Social Renew and placebo (time frame: Day 0 to 30). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Jun 2026.